



# Jillian M. Schurr-Hendrix

Associate

Intellectual Property

Dallas Office | +1.214.765.3684

jillian.schurr-hendrix@katten.com

**Jillian Schurr-Hendrix concentrates her practice on patent issues within the pharmaceutical industry. She represents a range of pharmaceutical companies in both *inter partes* review and complex patent litigation under the Hatch-Waxman Act.**

## Well-rounded experience leads to a broad knowledge base

In addition, Jillian is dedicated to pro bono practice. She has counseled clients at the Katten De Diego Legal Clinic and has assisted on many pro bono matters including Asylum and Civil Rights. Jillian was also a Board Member and co-founder of The Endometriosis Coalition, Inc. (The Endo Co) and assisted the organization with obtaining its 501(c)(3) federal tax-exempt status.

Prior to joining Katten, Jillian worked as a disease intervention specialist at both the state and local levels where she controlled disease outbreaks through investigation and interviewing techniques. Additionally, she worked as a clinical research assistant recruiting human subjects for clinical trials. Jillian uses her experience and background in the health care industry to advise clients in the pharmaceutical industry.

## Practices

---

- Hatch-Waxman Litigation
- Intellectual Property
- Intellectual Property Litigation
- Patent Litigation and Patents
- Pharmaceutical and Life Sciences Litigation

## Industries

---

- Pharmaceutical and Life Sciences

## Education

---

- JD, Northwestern University
- BS, Michigan State University

## Bar Admissions

---

- Arkansas
- Illinois
- Kansas
- Texas

# Jillian M. Schurr-Hendrix

Associate

---

## Recognitions

---

Recognized or listed in the following:

- *ANDA Litigation Intelligence Report*
  - Best Performing ANDA Attorneys Representing Defendants, 2021–2024
  - Most Active ANDA Attorneys Representing Defendants, Top 100, 2021–2023; Top 50, 2024-2025
  - Best Performing ANDA Attorneys Overall (Representing Plaintiffs or Defendants), 2024
  - Most Active ANDA Attorneys Overall (Representing Plaintiffs and Defendants), Top 100, 2023; 2024

## News

---

- Katten Secures Federal Circuit Victory for Mylan Pharmaceuticals (May 14, 2026)
- Katten Earns Repeat Recognition as a Top Three ANDA Litigation Firm (September 2, 2025)
- Katten Ranked Top Three Firm in ANDA Litigation (September 3, 2024)
- Another Precedent-Setting Remand from the Federal Circuit Garners Media Attention (April 2, 2024)
- Katten's IP Litigation Team Prevails at Trial, Securing Patent Win for Mylan Pharmaceuticals (March 15, 2024)
- Precedent-Setting Patent Win in Federal Circuit Creates Media Buzz From *Bloomberg Law*, *Reuters*, and More (November 7, 2023)
- Katten Ranked Top Three Firm in Hatch-Waxman Litigation (September 5, 2023)
- Katten Ranks Among Top Three Most Active Law Firms in ANDA Litigation (August 22, 2022)
- Report: The Best Hatch-Waxman Law Firms of 2021 | *IP Watchdog* (October 18, 2021)
- Katten Ranked in Top Five Most Active Law Firms for ANDA Litigation (August 23, 2021)
- Katten Assists in Farasis Energy's Restructuring, Listing on SSE STAR Market and Its Strategic Cooperation With Daimler (July 20, 2020)

# Jillian M. Schurr-Hendrix

Associate

---

## Publications

---

- Biosimilars Litigation and Client Counseling (March 18, 2025)
- Increased Scrutiny by Federal Trade Commission of Orange Book Listings (October 2024)
- New York Passes Revised Automatic Renewal Law (December 4, 2020)
- Don't Fear IP-Antitrust 'Turducken' in Reverse-Payment Cases (November 24, 2020)
- The Balance Between Obviousness and Written Description — Lessons Learned from Recent Decisions (August 5, 2020)
- California Enacts "Reverse-Payment" Law Aimed at Patent Settlements — An Initial Look ... Assuming It Is Upheld (May 19, 2020)